20:45
2026-08-19
stockhead.com.au
artificial-intelligence
Dr Boreham’s Crucible: Diversification has seen Amplia make ‘fashion statement’
Amplia (ASX:ATX), a pancreatic cancer drug developer, has diversified its clinical program by partnering with Eli Lilly to combine its lead compound narmafotinib (AMP-945) with an Eli Lilly KRAS inhib…